HAE Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 10.76% compared to Haemonetics's net margin of 12.41%. Haemonetics's return on equity of 14.16% beat Boston Scientific's return on equity of 8.96%.

Haemonetics has a consensus price target of $96.80, signalling upside risk potential of 47.74%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 19%. Given that Haemonetics has higher upside potential than Boston Scientific, analysts believe Haemonetics is more attractive than Boston Scientific.

Haemonetics has a beta of 0.430, which suggesting that the stock is 57.014% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Haemonetics quarterly revenues are $348.5M, which are smaller than Boston Scientific quarterly revenues of $4.6B. Haemonetics's net income of $37.5M is lower than Boston Scientific's net income of $566M. Notably, Haemonetics's price-to-earnings ratio is 25.80x while Boston Scientific's PE ratio is 77.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.44x versus 8.62x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 10.76% compared to Haemonetics's net margin of 4.03%. Haemonetics's return on equity of 14.16% beat Globus Medical's return on equity of 2.56%.

Haemonetics has a consensus price target of $96.80, signalling upside risk potential of 47.74%. On the other hand Globus Medical has an analysts' consensus of $98.69 which suggests that it could grow by 38.93%. Given that Haemonetics has higher upside potential than Globus Medical, analysts believe Haemonetics is more attractive than Globus Medical.

Haemonetics has a beta of 0.430, which suggesting that the stock is 57.014% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.608%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Haemonetics quarterly revenues are $348.5M, which are smaller than Globus Medical quarterly revenues of $657.3M. Haemonetics's net income of $37.5M is higher than Globus Medical's net income of $26.5M. Notably, Haemonetics's price-to-earnings ratio is 25.80x while Globus Medical's PE ratio is 94.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.44x versus 3.88x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health has a net margin of 10.76% compared to Haemonetics's net margin of 1.03%. Haemonetics's return on equity of 14.16% beat Phibro Animal Health's return on equity of 7.41%.

Haemonetics has a consensus price target of $96.80, signalling upside risk potential of 47.74%. On the other hand Phibro Animal Health has an analysts' consensus of $21.00 which suggests that it could fall by -1.18%. Given that Haemonetics has higher upside potential than Phibro Animal Health, analysts believe Haemonetics is more attractive than Phibro Animal Health.

Haemonetics has a beta of 0.430, which suggesting that the stock is 57.014% less volatile than S&P 500. In comparison Phibro Animal Health has a beta of 0.584, suggesting its less volatile than the S&P 500 by 41.576%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health offers a yield of 2.26% to investors and pays a quarterly dividend of $0.12 per share. Haemonetics pays -- of its earnings as a dividend. Phibro Animal Health pays out 804.72% of its earnings as a dividend.

Haemonetics quarterly revenues are $348.5M, which are larger than Phibro Animal Health quarterly revenues of $309.3M. Haemonetics's net income of $37.5M is higher than Phibro Animal Health's net income of $3.2M. Notably, Haemonetics's price-to-earnings ratio is 25.80x while Phibro Animal Health's PE ratio is 44.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.44x versus 0.78x for Phibro Animal Health. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 10.76% compared to Haemonetics's net margin of 26.88%. Haemonetics's return on equity of 14.16% beat ResMed's return on equity of 25.56%.

Haemonetics has a consensus price target of $96.80, signalling upside risk potential of 47.74%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 20.17%. Given that Haemonetics has higher upside potential than ResMed, analysts believe Haemonetics is more attractive than ResMed.

Haemonetics has a beta of 0.430, which suggesting that the stock is 57.014% less volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.92% to investors and pays a quarterly dividend of $0.53 per share. Haemonetics pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haemonetics quarterly revenues are $348.5M, which are smaller than ResMed quarterly revenues of $1.3B. Haemonetics's net income of $37.5M is lower than ResMed's net income of $344.6M. Notably, Haemonetics's price-to-earnings ratio is 25.80x while ResMed's PE ratio is 26.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.44x versus 6.71x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.